SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

VARANI, Katia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 50.270
AS - Asia 26.499
EU - Europa 16.804
SA - Sud America 4.130
Continente sconosciuto - Info sul continente non disponibili 766
AF - Africa 554
OC - Oceania 47
AN - Antartide 1
Totale 99.071
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 49.026
SG - Singapore 9.385
CN - Cina 6.807
BR - Brasile 3.147
VN - Vietnam 3.036
DE - Germania 2.996
FI - Finlandia 2.929
IT - Italia 2.721
UA - Ucraina 2.390
HK - Hong Kong 2.175
TR - Turchia 1.935
GB - Regno Unito 1.502
FR - Francia 950
SE - Svezia 947
RU - Federazione Russa 755
BD - Bangladesh 641
JP - Giappone 634
CA - Canada 618
IN - India 539
PL - Polonia 533
MX - Messico 386
AR - Argentina 345
ID - Indonesia 254
NL - Olanda 249
ZA - Sudafrica 203
IQ - Iraq 187
ES - Italia 163
EC - Ecuador 161
CO - Colombia 146
BE - Belgio 128
PK - Pakistan 114
VE - Venezuela 102
LT - Lituania 98
UZ - Uzbekistan 90
SA - Arabia Saudita 87
MA - Marocco 85
AT - Austria 78
MY - Malesia 75
CZ - Repubblica Ceca 73
PH - Filippine 73
CL - Cile 72
AE - Emirati Arabi Uniti 67
TN - Tunisia 61
KE - Kenya 55
PY - Paraguay 54
JM - Giamaica 53
CR - Costa Rica 43
JO - Giordania 43
AU - Australia 35
UY - Uruguay 34
IL - Israele 33
CH - Svizzera 32
EG - Egitto 32
KR - Corea 32
NP - Nepal 32
PE - Perù 32
IE - Irlanda 30
BO - Bolivia 29
DZ - Algeria 29
HN - Honduras 27
IR - Iran 26
RO - Romania 25
AL - Albania 24
TT - Trinidad e Tobago 23
TW - Taiwan 23
AZ - Azerbaigian 22
KZ - Kazakistan 20
PT - Portogallo 20
EU - Europa 18
TH - Thailandia 18
ET - Etiopia 17
LB - Libano 16
BG - Bulgaria 15
KG - Kirghizistan 15
OM - Oman 15
PS - Palestinian Territory 15
SY - Repubblica araba siriana 15
BH - Bahrain 14
DO - Repubblica Dominicana 14
GT - Guatemala 14
HU - Ungheria 14
RS - Serbia 14
LV - Lettonia 13
HR - Croazia 12
MD - Moldavia 12
NO - Norvegia 12
SV - El Salvador 12
AM - Armenia 11
BA - Bosnia-Erzegovina 11
BY - Bielorussia 11
GR - Grecia 11
NI - Nicaragua 11
CI - Costa d'Avorio 10
SN - Senegal 10
NZ - Nuova Zelanda 9
PA - Panama 9
AO - Angola 8
CG - Congo 8
PR - Porto Rico 8
QA - Qatar 8
Totale 98.171
Salva come PNG Salva come JPEG
Città #
Singapore 6.061
Ashburn 5.064
Woodbridge 3.959
San Jose 3.490
Fairfield 3.397
Jacksonville 2.617
Chandler 2.501
Houston 2.463
Helsinki 2.234
Ann Arbor 2.135
Hong Kong 2.131
Beijing 2.081
Santa Clara 2.079
Dallas 1.564
Council Bluffs 1.442
Wilmington 1.430
Seattle 1.364
Cambridge 1.111
Ho Chi Minh City 989
Izmir 897
Los Angeles 872
Nanjing 786
Hanoi 702
New York 653
Tokyo 605
Princeton 587
Ferrara 527
Munich 527
Lauterbourg 486
Warsaw 484
Boardman 479
Milan 424
São Paulo 324
Shanghai 322
San Diego 311
Nanchang 252
Orem 249
Shenyang 236
Mexico City 234
Buffalo 205
London 203
Chicago 197
Tianjin 191
Toronto 188
Turku 188
Dearborn 179
Hefei 174
Bremen 167
Montreal 166
Frankfurt am Main 163
Changsha 158
Chennai 156
The Dalles 155
Falkenstein 153
Brooklyn 150
Hebei 148
Jakarta 144
Da Nang 143
Addison 140
Denver 138
Jiaxing 138
Phoenix 136
Haiphong 129
San Francisco 126
Atlanta 124
Brussels 122
Rome 112
Johannesburg 108
Manchester 104
Moscow 99
San Mateo 99
Stockholm 97
Jinan 95
Rio de Janeiro 95
Zhengzhou 93
Falls Church 90
Bologna 88
Norwalk 85
Amsterdam 83
Boston 82
Kunming 82
Dong Ket 81
Tashkent 80
Poplar 78
Baghdad 76
Guangzhou 76
Mountain View 70
Philadelphia 70
Ankara 64
Biên Hòa 62
Columbus 62
Auburn Hills 59
Belo Horizonte 59
Düsseldorf 58
Orange 58
Washington 58
Charlotte 57
Hải Dương 56
Ningbo 55
Mumbai 54
Totale 64.995
Salva come PNG Salva come JPEG
Nome #
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists 3.125
Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies 429
Pharmacology of Adenosine Receptors: The State of the Art 424
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 388
Dose and time effects of caffeine intake on human platelet adenosine A2A receptors: functional and biochemical aspects 374
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 333
Caffeine alters A(2A) adenosine receptors and their function in human platelets 331
A glance at adenosine receptors: Novel target for antitumor therapy 322
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 317
Alterazioni dei recettori alfa(2) adrenergici delle piastrine umane nell'ipertensione essenziale 314
Psychostimulant effect of the synthetic cannabinoid JWH-018 and AKB48. Behavioural, neurochemical and Dopamine transporter scan imaging studies in mice 310
Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety 307
Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455 301
A(2B) adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway 295
The A3 adenosine receptor: history and perspectives 294
Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice 292
Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice 286
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 286
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 284
Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? 281
Recettori e trasduzione del segnale 278
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 277
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells 275
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease 273
Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields 271
Pulsed Electromagnetic Fields: A Novel Attractive Therapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia 270
A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release 268
Repeated dosing with NCX1404, a nitric oxide-donating pregabalin, re-establishes normal nociceptive responses in mice with streptozotocin-induced painful diabetic neuropathy 266
Recettori e trasduzione del segnale 265
A1 and A3 adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes 264
Adenosine receptors and human melanoma 264
[H-3]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors 264
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 262
Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts 261
[H-3]-MRE 2029-F20, a selective antagonist radioligand for the human A(2B) adenosine receptors 261
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats 257
The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles 257
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 254
6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors 251
Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter 251
“Bridging the Gap” Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era 250
Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 249
New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A 3 adenosine receptor antagonists 249
Role and function of A2A and A3 adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis 247
Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. 247
A(2A) adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients 247
History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents 246
Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies 245
Ala scan analogues of HOE 140. Synthesis and biological activities 244
Comparison of prazosin, terazosin and tamsulosin: Functional and binding studies in isolated prostatic and vascular human tissues 244
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2. 243
Alteration of A3 adenosine receptors in human neutrophils and low frequency electromagnetic fields 243
Adenosine A1 receptors in the rat brain in the kindling model of epilepsy 242
5-heteroarylcarbamoylamino-pyrazolo-triazolo pyrimidines as hA3 adenosine receptor antagonists. 241
Multiple sclerosis lymphocytes upregulate A(2A) adenosine receptors that are antiinflammatory when stimulated 241
HIF-1 neuroprotection through erythropoietin increase in hypoxia: a role for A1 adenosine receptors 239
Cannabinoid CB2 receptor attenuates morphine-induced inflammatory responses in activated microglial cells 239
Biological activity of for-Met-Leu-Phe-OMe analogs: relevant substitutions specifically trigger killing mechanisms in human neutrophils 238
Adenosine modulates vascular endothelial growth factor expression via hypoxiainducible factor-1 in human glioblastoma cells. 237
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 236
The activation of μ-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia 235
Adenosine signaling contributes to ethanol-induced fatty liver in mice 234
A3 Receptors are Overexpressed in Pleura from Mesothelioma Patients and Reduce Cell Growth via Akt/NF-kB Pathway. 232
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 231
Adenosine receptor targeting in health and disease 230
Alteration of adenosine receptore in patients with chronic obstructive pulmonary disease 229
Current status of A1 adenosine receptor allosteric enhancers 228
ALTERATION OF ADENOSINE RECEPTORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 227
[3H]-MRE 2029-F20, a novel selective antagonist radioligand, for the pharmacological and biochemical characterization of A2B receptors. 227
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A2A Adenosine Receptor Inverse Agonists with Antinociceptive Activity 227
Binding thermodynamics and intrinsic activity of adenosine A1 receptor ligands 226
A3 adenosine receptors are overexpressed in pleura from patients with mesothelioma and reduce malignant mesothelioma cell growth 226
van't Hoff Based Thermodynamics 226
A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study 225
Biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptors 225
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 224
A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus 224
Targeting A3 and A2A adenosine receptors in the fight against cancer 224
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 223
The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells 223
7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A(2A) adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility 223
Effects of doxazosin and propranolol on A2A adenosine receptors in essential hypertension 222
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells 221
Asymmetrical nitrido tc-99m heterocomplexes as potential imaging agents for benzodiazepine receptors 220
[3H]MRE2029F20 a new selective antagonist radioligand for the human A2B adenosine receptors. 220
7-substituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: importance of modifications at the side chain on the activity and solubility. 220
Structure-activity relationship studies of a new series of imidazo[2,1-f] purinones as potent and selective A3 adenosine receptor antagonists 220
P2X1 and P2X3 Purinergic Receptors Differentially Modulate the Inflammatory Response in Human Osteoarthritic Synovial Fibroblasts 220
Adenosine modulates HIF-1, VEGF, IL-8 and foam cells formation in a human model of hypoxic foam cells 220
3H SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes 220
Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors 220
Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields 220
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists 219
THERMODYNAMICS OF A2B ADENOSINE RECEPTOR BINDING DISCRIMINATES AGONISTIC FROM ANTAGONISTIC BEHAVIOUR 219
Synthesis and pharmacology of 6-substituted benztropines: Discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter 219
Pathological overproduction: the bad side of adenosine 219
Receptor binding at two different temperatures to discriminate agonist and antagonist behaviour of adenosine A1 receptor ligands in rat brain 218
4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies 218
Microwave-assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A(1) receptor 218
F638 a nitric oxide (NO)-donating gabapentin, NCX 1236, reverses the development of mechanical allodynia in streptozotocin-treated diabetic mice. 217
Totale 28.388
Salva come PNG Salva come JPEG
Categoria #
all - tutte 421.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 9.268
Totale 430.343
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.467 0 0 340 225 245 210 232 269 193 432 731 1.590
2022/20235.734 592 432 176 795 954 821 269 458 700 46 296 195
2023/20242.851 289 377 142 83 316 343 136 209 57 72 77 750
2024/202512.275 311 354 946 618 1.431 1.133 460 739 1.729 1.390 1.711 1.453
2025/202637.587 3.432 1.629 3.585 4.462 4.967 2.339 3.975 1.789 5.243 3.973 1.420 773
2026/20274.836 1.253 2.250 1.333 0 0 0 0 0 0 0 0 0
Totale 99.071